Here are the DEF 14A proxy statements from Climb Bio, Inc. (CLYM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CLYM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLYM filings page.
Climb Bio, Inc. will hold its 2026 annual stockholder meeting virtually on June 5, 2026 at 9:00 a.m. Eastern via www.proxydocs.com/CLYM, with a record date of April 7, 2026.
Stockholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, amending the certificate of incorporation to change how directors may be removed for cause, and amending the 2021 Equity Incentive Plan so its automatic share pool increase includes prefunded warrants. The company describes its classified board, committee structure, independence determinations, insider-trading and clawback policies, and executive compensation. In 2025, the CEO earned a $669,500 salary and $2.92 million in total compensation, and the auditor billed $686,400 in fees. A quorum requires a majority of outstanding common shares, noted as approximately 47,768,543 shares.